{'fraction_non_alphanumeric': 0.01584786053882726, 'fraction_numerical': 0.005546751188589541, 'mean_word_length': 5.544041450777202, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Incorporating psychiatric pharmacogenetics into family practice.

Given that the bulk of medication treatment occurs in primary care, pharmacogenetic (PGx) testing within family practice is likely to be an important step for the advancement of personalized medicine. In terms of psychiatric medications, 75–80% of prescriptions are written by primary care providers. Our research study delivers and evaluates PGx testing for psycho tropic drugs (antidepressants and anti psychotics) and our recent expansion to primary care clinics has been very well received by physicians and patients alike. We have demonstrated the feasibility of delivering PGx reports on a panel of CYP450 variants to family physicians in a manner that is generally understood and easily converted into actionable decisions by the physician. We expect that PGx testing carried out at the start of treatment, or for patients with problematic medication histories, will lead to more rapid clinical success with fewer side effects and complications. “Our pharmacogenetic report informs the doctor regarding the genetic status of five hepatic drug metabolism enzymes, and links each enzyme to a list of antidepressant or antipsychotic medications that are primarily metabolized by that enzyme.”